Related Experiment Video
Updated: Jun 4, 2026
08:27
Real-time Cytotoxicity Assays in Human Whole Blood
Published on: November 7, 2014
Impact of high-throughput screening in biomedical research
Ricardo Macarron1, Martyn N Banks, Dejan Bojanic
1Department of Sample Management Technologies, GlaxoSmithKline, Mail Stop UP 12-200, 1250S Collegeville Rd, Collegeville, Pennsylvania 19426, USA. ricardo.macarron@gsk.com
Nature Reviews. Drug Discovery
|March 2, 2011
Summary
High-throughput screening (HTS) is wrongly blamed for declining pharmaceutical productivity and stifled creativity. This article argues HTS is a vital tool for discovering novel chemotypes, essential for drug discovery.
Area of Science:
- Drug discovery and development
- Medicinal chemistry
- Pharmacology
Background:
- High-throughput screening (HTS) faces criticism for potentially decreasing pharmaceutical industry productivity.
- Concerns exist that HTS may hinder the creative processes essential for drug discovery.
- This perspective challenges the negative perceptions surrounding HTS.
Approach:
- The article presents a case for the continued and expanded use of HTS.
- It positions HTS as an integral component of a robust scientific toolkit.
- The focus is on leveraging HTS for identifying novel chemical entities.
Key Points:
- HTS is not inherently detrimental to productivity or creativity in drug discovery.
- The effective application of HTS is crucial for innovation.
- New chemotypes are vital for advancing pharmaceutical pipelines.
Conclusions:
- The article aims to debunk myths surrounding HTS.
- It advocates for HTS as a valuable and proven methodology.
- Wider adoption of HTS is essential for discovering novel chemotypes and driving pharmaceutical progress.
